Recipharm January 11, 2020
Tag: series A round , BW Therapeutics , Strategic Partnering Initiatives
BW Therapeutics, Inc. announced today the opening of its Series A fundraising process and kick-off of a strategic partnering initiative. The funds raised will be used to further the development of its TYN-21 program, a novel, proprietary formulation of paclitaxel that is expected to provide equivalency to Abraxane, a leading oncology drug.
BW Therapeutics CEO and Co-Founder, Kevin Sill, Ph.D., commented, "We look forward to partnering with investors to join us in taking our TYN-21 program to the next stage and ultimately a partnership with a major biopharma partner." Brad Sullivan, Ph.D., COO and Co-Founder said, "Our market research has revealed a desire for a cost-competitive alternative to Abraxane. TYN-21 is well positioned to meet this need due to its rapid and inexpensive development path."
About BW Therapeutics:
BW Therapeutics was founded in 2019 as a biotechnology company focused on the development of TYN-21, a 505(b)(2) formulation of Abraxane. BW Therapeutics intends to develop TYN-21 through NDA approval with the proceeds from its Series A financing.
Register as Visitor to CPhI China 2020!
-----------------------------------------------------------------------
Editor's Note:
En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,
for any copyright disputes involved in the reproduced articles,
please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: